GPT-Rosalind vs DeepSeek V4 Pro: Life-sciences reasoning at 13x the price

GPT-Rosalind, Open​AI's life-sciences reasoning model that left research preview on September 11, 2026, and DeepSeek V4 Pro, Deep​Seek's 1.6T-parameter flagship MoE, sit at opposite ends of the price spectrum: Rosalind lists at $5.00/$25.00 per 1M tokens effective October 5, while DeepSeek V4 Pro runs $0.66/$1.98 off-peak — a 13x gap on input, 8x on output. The open-weights Chinese lab's model has been a fixture of the cost-efficiency conversation since its April 2026 release; Rosalind is the newest entry in the specialized frontier. This matchup is less about which is "better" than about what each model is actually for.

Two very different design points

DeepSeek V4 Pro is a 1.6T-parameter mixture-of-experts flagship with 49B active parameters per token, a 1M-token context window, and up to 384K output tokens. It is a text-in/text-out reasoning model with hybrid reasoning and strong agentic tool use, and it has been served on OpenRouter since its April 2026 debut. GPT-Rosalind is purpose-built for life sciences: reasoning over molecules, proteins, genes, pathways, and disease-relevant biology, with tool use wired into a 50+ tool/database plugin ecosystem. They overlap only where biology touches general reasoning.

Rosalind's release history is itself the story: introduced April 16, 2026 to US-only trusted-access partners, expanded June 3 with GPT-5.5-class agentic coding and tool use, and on September 11, 2026 O​penAI announced it is out of research preview, available globally to eligible organizations through the trusted-access program. Billing for the gpt-rosalind-research model begins October 5, 2026 at $5.00/$25.00 per 1M tokens. DeepSeek V4 Pro's pricing, meanwhile, is a cost curve: $0.66/$1.98 off-peak, with peak-hour windows (01:00-04:00 and 06:00-10:00 UTC) at 2x, and a $0.022 cache read — all of it visible on a live provider list price.

The scoreboard

• Price — GPT-Rosalind $5.00 / $25.00 per 1M (cached input $0.50), effective Oct 5. DeepSeek V4 Pro $0.66 / $1.98 per 1M off-peak, peak 2x.

• AA Intelligence Index — DeepSeek V4 Pro: 36.3, #19 of 141. GPT-Rosalind: not tracked (specialized models absent from the general index).

• Speed — DeepSeek V4 Pro: p50 TTFT 1.17s, output ~68.8 tok/s per AA. GPT-Rosalind: no published latency; long-horizon tool calls expected.

• Params — DeepSeek V4 Pro: 1.6T total / 49B active. GPT-Rosalind: undisclosed, frontier-scale.

• Context window — Both 1M tokens. DeepSeek V4 Pro max output 384K; GPT-Rosalind uses file uploads through ChatGPT/Codex/API.

• Access — DeepSeek V4 Pro: open API, on OrcaRouter at list price. GPT-Rosalind: trusted-access application and qualification review.

• Domain evals — GPT-Rosalind: BixBench leading, 6/11 LABBench2 wins over GPT-5.4, +53.7% GeneBench, +18.0% MedChemBench, +19.6% LabWorkBench (all vendor-reported). DeepSeek V4 Pro: generalist, GPQA Diamond 92.8, no published life-sciences suite.

What the price gap buys

The 13x price difference is the headline, but it is a price for different goods. Rosalind's $25/M output buys a model that has been specifically tuned to reduce hallucinations in scientific contexts — O​penAI claims 40% lower hallucination rates than general models, vendor-measured — and to operate scientific tools correctly across multi-step workflows: literature review, sequence-to-function interpretation, experimental design, target prioritization. DeepSeek V4 Pro's $1.98/M output buys a generalist reasoning model with an outstanding cost-performance ratio, but no scientific-tool training, no domain-specific benchmarks, and no plugin ecosystem. For a research team, the question is whether domain accuracy is worth 13x the token price.

There is one number that cuts the other way. Rosalind's RNA-sequence result — exceeding the 95th percentile of 57 human AI-bio experts at Dyno Therapeutics — is a partner evaluation on a proprietary task with best-of-ten sampling, so it prices in heavy compute per call. DeepSeek V4 Pro's independent 36.3 AA Intelligence Index and 92.8 GPQA Diamond give it verifiable general reasoning strength at a fraction of the cost. The models are not substitutes; they are complements in the same lab.

The cost argument for DeepSeek V4 Pro

For high-volume scientific workloads — mass literature screening, bulk sequence annotation, embedding-scale extraction — DeepSeek V4 Pro's economics are transformative. At off-peak $0.66/$1.98, a million-token screening pass costs a few dollars, and the model's 1M context and 384K output handle long documents without chunking. Its peak-hour pricing is predictable and visible, so a batch pipeline can schedule around the 01:00-04:00 and 06:00-10:00 UTC windows and effectively halve the bill. This is the model for the parts of a research pipeline that are high-volume and low-ambiguity — the parts where a domain specialist would be wasted.

The quality argument for GPT-Rosalind

At the decision points — a target to prioritize, a cloning protocol to design, an RNA variant to interpret — a 13x price is defensible if the specialist is right more often. That is exactly the claim Rosalind makes, with vendor-reported evidence: leading BixBench performance, 6 of 11 LABBench2 tasks above GPT-5.4, and per-token gains on GeneBench, MedChemBench, and LabWorkBench. The hallucination-reduction claim, if it holds up in independent testing, is the strongest practical argument: in biology, a wrong answer is not a bad token, it is a wasted experiment or a wrong conclusion. No one has yet reproduced these numbers outside O​penAI, and until they do, treat them as vendor-reported but directionally credible.

Routing: one key, both models

The practical reality is that a modern research team needs both of these models, and this is exactly where a routing layer earns its keep. DeepSeek V4 Pro is on OrcaRouter at list price — $0.66/$1.98 off-peak, passed through with 0% markup — so high-volume generalist work flows through one API without a second contract or code change. Rosalind itself is not yet on any third-party router; it requires the trusted-access application directly. But you can already compose them in a single call using the routing DSL — low-ambiguity extraction to DeepSeek V4 Pro, high-stakes biological reasoning to a specialist endpoint — and automatic failover means if one provider's peak window hits, the request lands where it can. One key, both economics: the cost-efficient generalist for volume, the specialist for the decisions that matter.

Bottom line

Do not buy this matchup as either/or. GPT-Rosalind and DeepSeek V4 Pro solve different problems at prices that reflect those problems. If your work is biological discovery and your budget allows specialist reasoning at decision points, Rosalind is the purpose-built choice — after your organization clears trusted-access qualification, which is not a given. If your work is the high-volume, high-throughput, cost-sensitive majority of any research pipeline, DeepSeek V4 Pro at off-peak $0.66/$1.98 is the rational default, with independent benchmarks to back it. The winning architecture is both: route the volume to DeepSeek V4 Pro at list price, reserve the specialist for the moments where a wrong answer costs more than 13x the token price.